EMA Authorised: Fintepla (fenfluramine hydrochloride) — UCB Pharma S.A.

View source ↗

Summary

The EMA authorised Fintepla (fenfluramine hydrochloride) for epilepsies with myoclonic features, with orphan medicine designation; decision date 26 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myoclonic Epilepsy

Drugs mentioned

• Fintepla (Fenfluramine)

Snippet

Status: Authorised. Therapeutic area: Epilepsies, Myoclonic. MAH: UCB Pharma S.A.. Decision date: 26/03/2026. Orphan medicine